Antidepresan

Antidepresan
Antidepresan
Kelas obat-obatan
Pengenal kelas
Penggunaan	Gangguan depresi
Kode ATC	N06A
Data klinis
Drugs.com	Drug Classes
Consumer Reports	Best Buy Drugs
WebMD	MedicineNet RxList
Pranala luar
MeSH	D000928
	Dalam Wikidata

Antidepresan adalah sebuah obat yang digunakan untuk mengobati gangguan depresi mayor, beberapa gangguan kecemasan, beberapa kondisi nyeri kronis, dan untuk membantu mengelola beberapa kecanduan.^[1] Efek samping umum dari antidepresan termasuk mulut kering, penambahan berat badan, pusing, sakit kepala, dan disfungsi seksual.^[2]^[3]^[4]^[5]^[6]

Sebagian besar jenis antidepresan biasanya aman dikonsumsi, tetapi dapat menyebabkan meningkatnya pikiran untuk bunuh diri ketika dikonsumsi oleh anak-anak, remaja, dan dewasa muda. Sindrom penghentian dapat terjadi setelah menghentikan antidepresan yang menyerupai depresi berulang.

Jenis

Berikut meeupakan jenis obat antidepresan:

Selective Serotonin Re-uptake Inhibitor (SSRIs)

Dihentikan/ditarik

Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs)

Serotonin modulators and stimulators (SMSs)

Serotonin antagonist and reuptake inhibitors (SARIs)

Nefazodon (Dihentikan/ditarik di banyak negara)
Trazodon

Dihentikan/ditarik

Etoperidon

Norepinephrine reuptake inhibitors (NRIs)

Reboksetin
Teniloksazin – juga merupakan antagonis reseptor 5-HT_2A
Viloksazin – juga merupakan antagonis reseptor 5-HT_2B dan agonis reseptor 5-5-HT_2C

Hanya di luar label

Atomoksetin^[8]^[9]^[10]^[11]

Norepinephrine–dopamine reuptake inhibitors (NDRIs)

Antidepresan trisiklik

Antidepresan tetrasiklik

Monoamine Oxidase Inhibitors (MAOIs)

Antipsikotik atipikal

Lainnya

Perawatan tambahan

Obat kombinasi

Referensi

^ Jennings, Leigh (2018). "Chapter 4: Antidepressants". Dalam Grossberg, George T.; Kinsella, Laurence J. Clinical psychopharmacology for neurologists: a practical guide. Springer. hlm. 45–71. doi:10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9.
^ Healy D, Noury LJ, Manginb D (May 2018). "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". International Journal of Risk & Safety in Medicine. 29 (3): 125–134. doi:10.3233/JRS-180744. PMC 6004900 . PMID 29733030.
^ Bahrick AS (2008). "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence". The Open Psychology Journal. 1: 42–50. doi:10.2174/1874350100801010042.
^ Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K (May 2013). "Strategies for managing sexual dysfunction induced by antidepressant medication". The Cochrane Database of Systematic Reviews. 5 (5): CD003382. doi:10.1002/14651858.CD003382.pub3. PMID 23728643.
^ Kennedy SH, Rizvi S (April 2009). "Sexual dysfunction, depression, and the impact of antidepressants". Journal of Clinical Psychopharmacology. 29 (2): 157–64. doi:10.1097/jcp.0b013e31819c76e9. PMID 19512977.
^ Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277), 11 June 20191, EMA/PRAC/265221/2019, Pharmacovigilance Risk Assessment Committee (PRAC)
^ Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2-3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
^ Fedder D, Patel H, Saadabadi A (March 2023). "Atomoxetine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29630286.
^ Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (December 2011). "The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects". CNS Neurosci Ther. 17 (6): 723–32. doi:10.1111/j.1755-5949.2010.00217.x. PMC 6493872 . PMID 21155988.
^ Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90. PMID 19752841.
^ Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8. doi:10.4088/JCP.13r08851. PMID 25295426.

Pranala luar

Media terkait Antidepressants di Wikimedia Commons

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Artikel bertopik kedokteran atau medis ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

[Jennings2018-1] Jennings, Leigh (2018). "Chapter 4: Antidepressants". Dalam Grossberg, George T.; Kinsella, Laurence J. Clinical psychopharmacology for neurologists: a practical guide. Springer. hlm. 45–71. doi:10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9.

[2] Healy D, Noury LJ, Manginb D (May 2018). "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". International Journal of Risk & Safety in Medicine. 29 (3): 125–134. doi:10.3233/JRS-180744. PMC 6004900 . PMID 29733030.

[Bahrick-3] Bahrick AS (2008). "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence". The Open Psychology Journal. 1: 42–50. doi:10.2174/1874350100801010042.

[4] Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K (May 2013). "Strategies for managing sexual dysfunction induced by antidepressant medication". The Cochrane Database of Systematic Reviews. 5 (5): CD003382. doi:10.1002/14651858.CD003382.pub3. PMID 23728643.

[5] Kennedy SH, Rizvi S (April 2009). "Sexual dysfunction, depression, and the impact of antidepressants". Journal of Clinical Psychopharmacology. 29 (2): 157–64. doi:10.1097/jcp.0b013e31819c76e9. PMID 19512977.

[6] Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277), 11 June 20191, EMA/PRAC/265221/2019, Pharmacovigilance Risk Assessment Committee (PRAC)

[Tatsumi1997-7] Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2-3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.

[pmid29630286-8] Fedder D, Patel H, Saadabadi A (March 2023). "Atomoxetine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29630286.

[pmid21155988-9] Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (December 2011). "The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects". CNS Neurosci Ther. 17 (6): 723–32. doi:10.1111/j.1755-5949.2010.00217.x. PMC 6493872 . PMID 21155988.

[pmid19752841-10] Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90. PMID 19752841.

[pmid25295426-11] Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8. doi:10.4088/JCP.13r08851. PMID 25295426.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]